Third funding period for SFB 1074 approved by the DFG Congratulations to all!

Summary of the Research Program

The focus of cancer drug development has shifted from conventional chemotherapy to therapeutics targeting molecular lesions of cancer cells. Despite major efforts to catalogue genetic lesions that drive human cancers, a major challenge remains to integrate the findings from basic science and clinical investigations for improved patient outcome.
This Collaborative Research Center (CRC) aims to bridge this gap in a highly focused area of cancer research, that is, acute and chronic leukemias, diseases which are most prevalent in the elderly population. Ulm University has a long-standing commitment to cutting-edge basic, translational, and clinical research on hematopoietic malignancies, reflected by a large number of research groups focusing on diverse aspects of leukemia biology, as well as some of the largest biobanks and most prestigious clinical programs in this area.
Research within the CRC is organized in two Project Groups which closely interact with each other to fully exploit the potential of combining excellent basic science with clinical expertise. Projects in Group A use a broad spectrum of physiologically relevant in vitro and in vivo experimental systems to investigate cellular and molecular mechanisms of leukemogenesis. Projects in Group B have a strong translational aspect and aim towards the genetic, epigenetic, and functional characterization of leukemia samples from patients with acute and chronic leukemia and/or human-derived experimental systems.
In summary, the proposed CRC provides a superb opportunity to realize the concept of translational research “from bench to bedside and back” in acute and chronic leukemias. It is hoped that this approach will substantially contribute to improved understanding of leukemia biology, and, importantly, to a better clinical management of patients with these diseases.

Third funding period for leukemia Collaborative Research Center:
DFG supports Ulm cancer research with 11 million Euros. Read more

Ulmer Krebsforscher geehrt
Professor Dr. Hartmut Döhner erhählt zwei hohe internationale Auszeichnungen. Mehr lesen

Chronisch Lymphatische Leukämie: Neuer therapeutischer Ansatz den Krebszellen die zelloläre Unterstützung entziehen. Mehr lesen

Scientists at Ulm University among world's 'Highly Cited Researchers' 2019
Prof. Hartmut Döhner and Prof. Stephan Stilgenbauer among them. Read more

Heisenberg-Professur für Pamela Fischer-Posovszky
Fettgewebe verstehen, um Übergewicht zu bekämpfen. Mehr lesen

White Paper des Deutschen Stammzellnetzwerkes
Der steinige Weg in die klinische Anwendung. Mehr lesen

Meileinstein auf dem Weg zur Professorin
Ulmer Forscherinnen in das Wrangell-Habilitationsprogramm aufgenommen, darunter Dr. Julia Zinngrebe. Mehr lesen

"Highly Cited Researchers" 2018
Neun Uni-Forscher unter den weltweit einflussrechsten - unter ihnen Prof. Hartmut Döhner und Prof. Stephan Stilgenbauer. Mehr lesen


Prof. Dr. med. Hartmut Döhner

Department of Internal Medicine III
Ulm University
Albert-Einstein-Allee 23
89081 Ulm

Phone:  +49-731-500-45501
Fax:       +49-731-500-45505

Email:  hartmut.doehner(at)

Upcoming Events

* Due to the current global situation, seminars and events have been put on hold until further notice *